Sirtris diaspora

Several Sirtris Pharmaceuticals Inc. alums disclosed their next moves last week, including CEO Christoph Westphal. He will become president of SR One, the venture arm of GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), which has $600 million under management.

Sirtris was acquired by GSK for $651 million in 2008.Westphal stayed on as CEO and became an SVP and head of GSK's Centre of Excellence for External Drug Discovery (CEEDD). He will relinquish both positions, but will co-chair Sirtris' scientific advisory board, according to GSK spokesperson Melinda Stubbee...